In the last trading session, 1,240,645 shares of the Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) were traded, and its beta was 1.64. Most recently the company’s share price was $54.01, and it changed around -$0.82 or -0.02% from the last close, which brings the market valuation of the company to $3.76 Billion. AGIO currently trades at a discount to its 52-week high of $58.93, offering almost -9.11% off that amount. The share price’s 52-week low was $32.47, which indicates that the current value has risen by an impressive 39.88% since then. We note from Agios Pharmaceuticals, Inc.’s average daily trading volume that its 10-day average is 862.67 Million shares, with the 3-month average coming to 779.45 Million.
Agios Pharmaceuticals, Inc. stock received a consensus recommendation rating of Overweight, based on a mean score of 2. If we narrow it down even further, the data shows that none out of 12 analysts rate the stock as a Sell; another but none rate it as Overweight. Among the rest, 3 recommended AGIO as a Hold, whereas 9 deemed it a Buy, and no one rated it as Underweight. Agios Pharmaceuticals, Inc. is expected to report earnings per share of -$1.34 for the current quarter.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO): Trading Information
Although AGIO has showed a red trend with a performance of -1.5% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of $55.03 on Tuesday, Apr 06 increased the stock’s daily price by 1.85%. The company’s shares are currently up 0.25% year-to-date, but still up 0.1302 over the last five days. On the other hand, Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is 0.1% up in the 30-day period. We can see from the shorts that 6.26 Million shares have been sold at a short interest cover period of 0.01 day (s).
The consensus price target as assigned by Wall Street analysts is $63.8, which translates to bears needing to increase their stock price by 18.13% from its current value. Analyst projections state that AGIO is forecast to be at a low of $50 and a high of $80. In order for the stock price to hit the forecast high, the stock would need to surge +48.12% from its current level, while the stock would need to crash -7.42% from its current level to reach the projected low.
Agios Pharmaceuticals, Inc. (AGIO) projections and forecasts
Agios Pharmaceuticals, Inc. share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen +61.61 percent over the past six months and at a 22.15% annual growth rate that is well above the industry average of 14.8%. However, despite this, analysts have decided to cut back on their fiscal year 2021 revenue estimates. The rating firms predict that it will lose -127.1% in revenue this quarter, and will report a decline of -17.6% in the next quarter. The year-over-year growth rate is expected to be -56.7%, down from the previous year.
Consensus estimates provided by 9 financial analysts predict the company will bring in an average of $43.53 Million in revenue for the current quarter. 7 analysts expect Agios Pharmaceuticals, Inc. to make $16.76 Million in revenue for the quarter ending June 01, 2021. The company’s sales for the same quarters a year ago were $87.1 Million and $37.35 Million respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -50%. Forecasts for the next quarter put sales growth at -55.1%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -8.6%. Agios Pharmaceuticals, Inc. earnings are expected to increase by 30.8% in 2021, but the outlook is positive 40% per year for the next five years.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)’s Biggest Investors
Upon looking at major shareholders, it appears that insiders hold 11.28% of Agios Pharmaceuticals, Inc. shares, and 94.61% of them are in the hands of institutional investors. The stock currently has a share float of 106.63%. Agios Pharmaceuticals, Inc. stock is held by 302 institutions, with Wellington Management Group, LLP being the largest institutional investor. By Dec 30, 2020, it held 11.32% of the shares, which is about 7.88 Million shares worth $341.33 Million.
Vanguard Group, Inc. (The), with 8.08% or 5.63 Million shares worth $243.76 Million as of Dec 30, 2020, holds the second largest percentage of outstanding shares.
Vanguard Specialized-Health Care Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF were the top two Mutual Funds as of Oct 30, 2020. The former held 6435516 shares worth $257.87 Million, making up 9.25% of all outstanding shares. On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF held roughly 1.96 Million shares worth around $92.91 Million, which represents about 2.81% of the total shares outstanding.